These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Characterization of purinergic receptor expression in ARPKD cystic epithelia. Palygin O; Ilatovskaya DV; Levchenko V; Klemens CA; Dissanayake L; Williams AM; Pavlov TS; Staruschenko A Purinergic Signal; 2018 Dec; 14(4):485-497. PubMed ID: 30417216 [TBL] [Abstract][Full Text] [Related]
3. Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Yoshihara D; Kugita M; Sasaki M; Horie S; Nakanishi K; Abe T; Aukema HM; Yamaguchi T; Nagao S PLoS One; 2013; 8(12):e81480. PubMed ID: 24324698 [TBL] [Abstract][Full Text] [Related]
4. Disease stage characterization of hepatorenal fibrocystic pathology in the PCK rat model of ARPKD. Mason SB; Liang Y; Sinders RM; Miller CA; Eggleston-Gulyas T; Crisler-Roberts R; Harris PC; Gattone VH Anat Rec (Hoboken); 2010 Aug; 293(8):1279-88. PubMed ID: 20665806 [TBL] [Abstract][Full Text] [Related]
5. Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD. Gradilone SA; Masyuk TV; Huang BQ; Banales JM; Lehmann GL; Radtke BN; Stroope A; Masyuk AI; Splinter PL; LaRusso NF Gastroenterology; 2010 Jul; 139(1):304-14.e2. PubMed ID: 20399209 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of Mast Cell Degranulation With Cromolyn Sodium Exhibits Organ-Specific Effects in Polycystic Kidney (PCK) Rats. Jiang L; Fang P; Septer S; Apte U; Pritchard MT Int J Toxicol; 2018; 37(4):308-326. PubMed ID: 29862868 [TBL] [Abstract][Full Text] [Related]
7. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Masyuk TV; Masyuk AI; Torres VE; Harris PC; Larusso NF Gastroenterology; 2007 Mar; 132(3):1104-16. PubMed ID: 17383431 [TBL] [Abstract][Full Text] [Related]
8. Chronic blockade of 20-HETE synthesis reduces polycystic kidney disease in an orthologous rat model of ARPKD. Park F; Sweeney WE; Jia G; Akbulut T; Mueller B; Falck JR; Birudaraju S; Roman RJ; Avner ED Am J Physiol Renal Physiol; 2009 Mar; 296(3):F575-82. PubMed ID: 19129252 [TBL] [Abstract][Full Text] [Related]
9. Chronic treatment with lisinopril decreases proliferative and apoptotic pathways in autosomal recessive polycystic kidney disease. Jia G; Kwon M; Liang HL; Mortensen J; Nilakantan V; Sweeney WE; Park F Pediatr Nephrol; 2010 Jun; 25(6):1139-46. PubMed ID: 20229187 [TBL] [Abstract][Full Text] [Related]
10. Initial evaluation of hepatic T1 relaxation time as an imaging marker of liver disease associated with autosomal recessive polycystic kidney disease (ARPKD). Gao Y; Erokwu BO; DeSantis DA; Croniger CM; Schur RM; Lu L; Mariappuram J; Dell KM; Flask CA NMR Biomed; 2016 Jan; 29(1):84-9. PubMed ID: 26608869 [TBL] [Abstract][Full Text] [Related]
11. Renin-angiotensin system activation in congenital hepatic fibrosis in the PCK rat model of autosomal recessive polycystic kidney disease. Goto M; Hoxha N; Osman R; Wen J; Wells RG; Dell KM J Pediatr Gastroenterol Nutr; 2010 Jun; 50(6):639-44. PubMed ID: 20400910 [TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats. Torres VE; Sweeney WE; Wang X; Qian Q; Harris PC; Frost P; Avner ED Kidney Int; 2004 Nov; 66(5):1766-73. PubMed ID: 15496147 [TBL] [Abstract][Full Text] [Related]
13. Role of genetic modifiers in an orthologous rat model of ARPKD. O'Meara CC; Hoffman M; Sweeney WE; Tsaih SW; Xiao B; Jacob HJ; Avner ED; Moreno C Physiol Genomics; 2012 Aug; 44(15):741-53. PubMed ID: 22669842 [TBL] [Abstract][Full Text] [Related]
14. Development and characterization of a cholangiocyte cell line from the PCK rat, an animal model of Autosomal Recessive Polycystic Kidney Disease. Muff MA; Masyuk TV; Stroope AJ; Huang BQ; Splinter PL; Lee SO; Larusso NF Lab Invest; 2006 Sep; 86(9):940-50. PubMed ID: 16783394 [TBL] [Abstract][Full Text] [Related]
15. Accuracy and processing time of kidney volume measurement methods in rodents polycystic kidney disease models: superiority of semiautomated kidney segmentation. Doss MC; Mullen S; Roye R; Zhou J; Chumley P; Mrug E; Wallace DP; Qian F; Harris PC; Yoder BK; Kim H; Mrug M Am J Physiol Renal Physiol; 2023 Apr; 324(4):F423-F430. PubMed ID: 36794756 [TBL] [Abstract][Full Text] [Related]
16. The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD). Banales JM; Masyuk TV; Gradilone SA; Masyuk AI; Medina JF; LaRusso NF Hepatology; 2009 Jan; 49(1):160-74. PubMed ID: 19065671 [TBL] [Abstract][Full Text] [Related]
17. Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease. Wang X; Harris PC; Somlo S; Batlle D; Torres VE Nephrol Dial Transplant; 2009 Feb; 24(2):526-34. PubMed ID: 18826972 [TBL] [Abstract][Full Text] [Related]
18. Epithelial-to-mesenchymal transition in cyst lining epithelial cells in an orthologous PCK rat model of autosomal-recessive polycystic kidney disease. Togawa H; Nakanishi K; Mukaiyama H; Hama T; Shima Y; Sako M; Miyajima M; Nozu K; Nishii K; Nagao S; Takahashi H; Iijima K; Yoshikawa N Am J Physiol Renal Physiol; 2011 Feb; 300(2):F511-20. PubMed ID: 21084407 [TBL] [Abstract][Full Text] [Related]
19. Improved Structure and Function in Autosomal Recessive Polycystic Rat Kidneys with Renal Tubular Cell Therapy. Kelly KJ; Zhang J; Han L; Kamocka M; Miller C; Gattone VH; Dominguez JH PLoS One; 2015; 10(7):e0131677. PubMed ID: 26136112 [TBL] [Abstract][Full Text] [Related]
20. Knockout of Arkhipov SN; Potter DL; Geurts AM; Pavlov TS Am J Physiol Renal Physiol; 2019 Dec; 317(6):F1649-F1655. PubMed ID: 31630543 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]